Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on May 12, 2025

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin for the treatment of R/R …

ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence Has served as ElevateBio’s strategic advisor over the past year, working closely with the executive team to scale business and operations WALTHAM, …

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 …

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
SARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced it will host a management update webinar on …

Brag House, in partnership with Florida Gator Athletics and Learfield’s Florida Gators Sports Properties, Launches the Inaugural “Brag Gators Gauntlet” Series Baseball Edition at the University of Florida – A tournament Featuring Fortnite ahead of the …
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) (“Brag House” or the “Company”), the premier Gen Z engagement platform that operates at the intersection of gaming, college sports, and social interaction, today announced …

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a …

Aqua Sculpt Reviews & Complaints: Whether the 7-Second Ice Water Trick Works (Verified Info 2025)
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- At first, I was a little skeptical about Aquasculpt. I had heard a lot of buzz about it, but like most people, I wondered if it could live up to the hype. After giving it a try, though, I was genuinely …

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today …

Registration for 2025 World Astatine Community Meeting Now Open
NEW ORLEANS, May 12, 2025 (GLOBE NEWSWIRE) -- The first-ever U.S.-based meeting of the World Astatine Community will take place June 19-20, 2025 at the Sheraton in downtown New Orleans. The event will highlight public and private sector research and …

Collegium Announces $25 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it …

ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
Lead candidate Risvodetinib (ABLi-148009) is an oral, once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor that is the first to drive clearance of disease pathology in human Parkinson’s disease ABLi’s proprietary Re-engineering Approach …

Bioliberty Launches Lifehub Clinic to Transform Therapy through Soft Robotics and Gamified Exercises
EDINBURGH, United Kingdom and BOSTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Bioliberty, a medtech startup transforming the delivery of physical and occupational therapy, today announced the launch of its first product, Lifehub Clinic at Rehab Week being …

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “ …

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
LEIDEN, Netherlands …

Foresight Diagnostics to Participate in the Jefferies Global Healthcare Conference
BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”) a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced that Jake Chabon, PhD, …

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic …

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference …

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer …

AdsAdvisor Launches Globally To Accelerate Growth For Mobile Businesses With A Comprehensive Marketing Platform
AMSTERDAM, May 12, 2025 (GLOBE NEWSWIRE) -- AdsAdvisor, a comprehensive marketing platform, launches globally to provide mobile businesses with a robust solution for optimizing marketing performance and driving product growth. Designed to meet the diverse …